Compare Aspen Aerogels Inc (ASPN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aspen Aerogels Inc vs Recursion Pharmaceuticals Inc — how do they compare? Aspen Aerogels Inc trades at $5.25 (market cap $427.65M), while Recursion Pharmaceuticals Inc trades at $3.52 (market cap $1.89B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 4.4× Aspen Aerogels Inc's market cap, and Aspen Aerogels Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ASPN | RXRX | |
|---|---|---|
Market Cap | $427.65M | $1.89B |
Sector | Technology | Health |
52-Week High | $8.82 | $6.79 |
52-Week Low | $2.57 | $2.84 |
Enterprise Value | $382.60M | $1.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.
RXRX trades at $3.56, down 5.32% today, with a bullish technical signal from moving averages but concerning fundamentals. The company shows deep losses with a -851.51% net income margin and negative cash flow from operations, though it has beaten earnings estimates for three consecutive quarters. Analyst consensus is mixed with a $7.83 price target representing significant upside potential from current levels.
While technical indicators suggest near-term strength and analyst targets imply 120% upside, RXRX faces substantial execution risks as a pre-revenue biotech. The company's AI-driven drug discovery platform shows promise but requires successful clinical outcomes to justify its valuation. High cash burn and negative profitability metrics present significant challenges for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
